Bank Of New York Mellon Corp Cyclerion Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $31,260 - $85,800	-66,512 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$0.96 - $1.78 $268 - $498	-280 Reduced 0.42%	66,512 $74,000
Q2 2021 Aug 11, 2021	SELL	$2.18 - $4.29 $68,057 - $133,929	-31,219 Reduced 31.85%	66,792 $260,000
Q1 2021 May 13, 2021	SELL	$2.69 - $5.12 $5,514 - $10,496	-2,050 Reduced 2.05%	98,011 $273,000
Q4 2020 Feb 09, 2021	BUY	$2.25 - $7.12 $26,221 - $82,976	11,654 Added 13.18%	100,061 $306,000
Q3 2020 Nov 12, 2020	SELL	$3.46 - $8.39 $1,944 - $4,715	-562 Reduced 0.63%	88,407 $537,000
Q2 2020 Aug 12, 2020	SELL	$2.37 - $7.14 $17,026 - $51,293	-7,184 Reduced 7.47%	88,969 $525,000
Q1 2020 May 06, 2020	SELL	$2.46 - $5.84 $469 - $1,115	-191 Reduced 0.2%	96,153 $254,000
Q4 2019 Feb 14, 2020	BUY	$1.8 - $13.43 $19,330 - $144,224	10,739 Added 12.54%	96,344 $262,000
Q3 2019 Nov 07, 2019	BUY	$8.12 - $14.54 $64,204 - $114,967	7,907 Added 10.18%	85,605 $1.04 Million
Q2 2019 Aug 12, 2019	BUY	$9.6 - $22.85 $745,900 - $1.78 Million	77,698 New	77,698 $890,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.